🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Birmingham
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Birmingham, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 24 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
545
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 670 Birmingham 470 Glasgow 437 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca31 Janssen Research & Development, LLC17 Merck Sharp & Dohme LLC16 Bristol-Myers Squibb14 Eli Lilly and Company14
Site city
London2010 Manchester670 Birmingham470 Glasgow437 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Birmingham

470 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Ridge Augmentation Treatment Using OSSIX® BREEZE vs Jason®
NCT05584566Ridge Augmentation
Datum Dental LTD
Not applicable
65
Birmingham
2022-12-01
Active, closed
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Phase 3
822
Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool
2022-11-08
Active, closed
Xeltis Hemodialysis Access Graft: aXess Pivotal Study
NCT05473299End-stage Renal Disease
Xeltis
Not applicable
120
Birmingham, Glasgow
2022-11-04
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT05557695Chronic Lymphocytic Leukemia, CLL
AstraZeneca
Observational
287
Aylesbury, Bath, Birmingham, Bournemouth, Cardiff, Cornwall, Dartford, Derby
2022-10-17
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Eli Lilly and Company
Phase 3
1,500
Bath, Birmingham, Bristol, Chertsey, Crowborough, Guildford, London, Nottinghamshire
2022-10-10
Recruiting
Met Non Small Cell Cancer Registry (MOMENT)
NCT05376891Cancer
EMD Serono Research & Development Institute, Inc.
Observational
700
Torquay, Huddersfield, Bedford, Birmingham, Bournemouth, Cardiff, Chelsea, Harrow
2022-10-04
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC
Phase 2/3
201
Birmingham, Devon, Glasgow, London, Sheffield
2022-09-23
Active, closed
Multicenter Study to Evaluate the Clinical Outcome of the OmniTaper EV Implant in Single Tooth Restorations
NCT05355792Jaw, Edentulous
Dentsply Sirona Implants and Consumables
Not applicable
139
Maidstone, Birmingham
2022-09-22
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
NCT05461170Hepatitis D, Chronic
Vir Biotechnology, Inc.
Phase 2
95
Birmingham, London, Manchester
2022-09-17
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Biogen
Phase 2/3
450
London, Manchester, Birmingham, Leeds
2022-09-13
Active, closed
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
NCT05570058IPF, Fibrosis
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Active, closed
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940Colorectal Cancer
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Active, closed
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222NASH, Cirrhosis, Liver
Madrigal Pharmaceuticals, Inc.
Phase 3
845
Birmingham, Cambridge, London
2022-08-26
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Recruiting
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
NCT05489705Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
Observational
1,700
London, Manchester, Liverpool, Birmingham, Leeds, Cardiff
2022-08-16
Active, closed
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
NCT05502341HIV-1-infection
Gilead Sciences
Phase 2/3
689
Birmingham, Brighton, London
2022-08-16
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613Mucopolysaccharidosis II
Denali Therapeutics Inc.
Phase 2/3
65
London, Birmingham, Salford
2022-07-21
Active, closed
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934Eosinophilic Granulomatosis With Polyangiitis
GlaxoSmithKline
Phase 3
163
Birmingham, Cambridge, London
2022-07-14
Active, closed
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
NCT05392114Hereditary Angioedema
Ionis Pharmaceuticals, Inc.
Phase 3
154
Birmingham, Bristol, London
2022-07-13
Active, closed
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446Metastatic Colorectal Cancer
Pfizer
Phase 2
108
Aberdeen, Birmingham
2022-07-11
Active, closed
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Active, closed
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
NCT05429632Adult Acute Myeloid Leukemia
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
NCT05115110Spinal Muscular Atrophy (SMA)
Hoffmann-La Roche
Phase 2/3
97
Birmingham, Oxford
2022-06-02
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
Gilead Sciences
Phase 2
193
Birmingham, London
2022-05-30
Recruiting
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175Colitis, Ulcerative
Bristol-Myers Squibb
Phase 2/3
120
Birmingham, London
2022-05-30
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Manchester, Northwood, Birmingham
2022-03-24
Active, closed
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559Haemophilia A and B With and Without Inhibitors
Novo Nordisk A/S
Phase 3
153
Birmingham, Bristol, London
2022-03-24
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Recruiting
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
NCT05295433Methylmalonic Acidemia
ModernaTX, Inc.
Phase 1/2
56
Birmingham, Manchester
2022-03-08
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
740
Birmingham, Nottingham
2022-03-04
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320Crohn's Disease (CD)
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Penzance, Belfast, Birmingham, Blackpool, Cardiff, Durham, Enfield, Fowey
2022-02-07
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Active, closed
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Quell Therapeutics Limited
Phase 1/2
33
Birmingham, Cambridge, London
2022-01-21
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019Refractory Angina
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
Regeneron Pharmaceuticals
Phase 3
288
Sheffield, Birmingham
2021-12-14
Recruiting
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
By invitation
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
NCT05145010Achondroplasia
QED Therapeutics, a BridgeBio company
Phase 2
300
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Recruiting
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
NCT05130437Propionic Acidemia
ModernaTX, Inc.
Phase 1/2
50
Manchester, Birmingham, London
2021-11-09
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
309
Birmingham
2021-09-23
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136Primary Biliary Cholangitis, PBC
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
NCT04528082Behçet Disease
Amgen
Phase 3
60
Birmingham, Liverpool, Oxford
2021-09-09
Active, closed
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05035030Alagille Syndrome
Albireo, an Ipsen Company
Phase 3
62
Birmingham, London
2021-09-03
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Active, closed
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230Ulcerative Colitis
Pfizer
Phase 3
118
London, Birmingham
2021-08-12
Active, closed
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Pierre Fabre Medicament
Phase 2
190
Birmingham, London
2021-07-14
Recruiting
CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting
NCT05002543Cardiac Valve Disease
Corcym S.r.l
Observational
2,150
Birmingham, Bristol, London
2021-06-29
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Mirati Therapeutics Inc.
Phase 3
461
Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London
2021-06-24
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo
Phase 3
490
Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester
2021-05-21
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London
2021-05-12
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 2
170
Chelsea, London, Manchester, Birmingham
2021-05-07
By invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Birmingham, Leicester, Edinburgh, Glasgow, Manchester, Nottingham
2021-04-24
Recruiting
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT04159103Propionic Acidemia
ModernaTX, Inc.
Phase 1/2
77
Birmingham, London, Manchester
2021-04-15
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
Novo Nordisk A/S
Phase 3
1,205
Belfast, Birmingham, Coventry, Derby, Dundee, Exeter, Hull, Ipswich
2021-04-01
Active, closed
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 3
453
Birmingham, Edinburgh, Glasgow, Leicester, Manchester
2021-02-23
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
Bioverativ, a Sanofi company
Phase 3
261
London, Birmingham, Hampshire
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo
Phase 2
277
Birmingham, London, Manchester
2021-02-02
Recruiting
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
BioNTech SE
Phase 2/3
358
Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool
2021-01-07
Active, closed
International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach
NCT04572230Intracranial Aneurysm
Stryker Neurovascular
Observational
405
Birmingham, Edinburgh
2020-12-21
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308Primary Sclerosing Cholangitis
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Birmingham, Liverpool
2020-12-16
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
Non-ischemic Preservation of the Donor Heart in Heart Transplantation
NCT03991923Heart Transplantation
XVIVO Perfusion
Not applicable
230
Newcastle, Birmingham, Cambridge
2020-11-25
Active, closed
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
NCT04636697SARS-CoV-2 Infection
Medicago
Phase 2/3
30,918
Aberdeen, Birmingham, Bournemouth, Cardiff, Chelmsford, Chorley, Derby, Harrow
2020-11-19
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Birmingham, London, Salford
2020-10-01
Active, closed
AAV Gene Therapy Study for Subjects with PKU
NCT04480567Phenylketonuria (PKU)
BioMarin Pharmaceutical
Phase 1/2
100
Birmingham
2020-09-24
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
NCT04468984Myelofibrosis (MF)
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283Diffuse Large B-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Birmingham, London, Sandwich
2020-08-20
Active, closed
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963Ovarian Cancer, Breast Cancer
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT04509700B-Cell Malignancies
Incyte Corporation
Phase 2
112
Birmingham
2020-08-03
Rows per page Showing 301–400 of 470
Previous 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-uk/city/birmingham?page=4

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 24 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 470 of those studies with a site in Birmingham.

How many clinical trials are recruiting in Birmingham?

221 of the 470 studies on this page are recruiting new participants as of the 24 Sep 2026, 03:15 UTC sync. A further 7 have not yet opened recruitment, 227 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.